Genmab Logo

Genmab

Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.

GMAB | CO

Overview

Corporate Details

ISIN(s):
DK0010272202 (+2 more)
LEI:
529900MTJPDPE4MHJ122
Country:
Denmark
Address:
Carl Jacobsens Vej 30, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genmab is an international biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary antibody science and pioneering technology platforms to innovate next-generation treatments. Genmab's core activities involve the discovery, development, and commercialization of antibody-based products, often in collaboration with strategic partners. Its purpose is to improve the lives of patients by harnessing the power of antibodies to transform medical care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 18:55
Regulatory News Service
English 206.6 KB
2025-11-19 18:55
Director's Dealing
English 7.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 176.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 7.8 KB
2025-11-18 17:30
Regulatory News Service
English 244.6 KB
2025-11-18 17:30
Regulatory News Service
English 27.2 KB
2025-10-14 12:23
Earnings Release
English 216.5 KB
2025-10-14 12:23
Earnings Release
English 7.7 KB
2025-09-29 07:08
M&A Activity
English 25.9 KB
2025-09-29 07:08
M&A Activity
English 234.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 175.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 7.2 KB
2025-09-23 15:18
Major Shareholding Notification
English 2.9 MB
2025-09-09 20:57
Director's Dealing
English 7.1 KB
2025-09-09 20:57
Director's Dealing
English 202.5 KB

Automate Your Workflow. Get a real-time feed of all Genmab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genmab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genmab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioceltix S.A. Logo
Developing 'off-the-shelf' stem cell therapies for diseases in companion animals.
Poland
BCX
BIOCRYST PHARMACEUTICALS INC Logo
Develops oral small-molecule drugs for rare diseases like hereditary angioedema.
United States of America
BCRX
Biodexa Pharmaceuticals Plc Logo
Develops treatments for rare diseases, diabetes, and cancer using proprietary drug delivery tech.
United States of America
BDRX
Biofarm S.A. Logo
A top domestic manufacturer of pharmaceuticals, supplements, and soft gelatin capsules.
Romania
BIO
Biofrontera AG Logo
Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.
Germany
B8F
Biofrontera Inc. Logo
Biopharma firm commercializing photodynamic therapy & antibiotics for skin conditions.
United States of America
BFRI
BioGaia Logo
Develops and commercializes clinically proven probiotics for digestive health across all life stages.
Sweden
BIOG
Bio-Gate AG Logo
Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.
Germany
BIG1
BIOGEN INC. Logo
Develops innovative therapies for complex neurological and neurodegenerative conditions.
United States of America
BIIB
Bio Green Med Solution, Inc. Logo
Develops cancer medicines and supplies fire safety equipment for global markets.
United States of America
BGMS

Talk to a Data Expert

Have a question? We'll get back to you promptly.